Emerald Advisers LLC Has $45.32 Million Holdings in Insmed, Inc. (NASDAQ:INSM)

Emerald Advisers LLC trimmed its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 13.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 594,013 shares of the biopharmaceutical company's stock after selling 90,623 shares during the quarter. Insmed makes up about 2.0% of Emerald Advisers LLC's portfolio, making the stock its 4th biggest holding. Emerald Advisers LLC owned 0.33% of Insmed worth $45,317,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the stock. National Bank of Canada FI grew its stake in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 147 shares in the last quarter. M&T Bank Corp grew its stake in Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. Snowden Capital Advisors LLC grew its stake in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after purchasing an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. grew its stake in Insmed by 3.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,314 shares of the biopharmaceutical company's stock valued at $436,000 after purchasing an additional 225 shares in the last quarter.

Insmed Price Performance

NASDAQ:INSM traded up $1.72 during trading hours on Wednesday, hitting $104.59. The company's stock had a trading volume of 3,691,327 shares, compared to its average volume of 2,300,750. The stock has a fifty day simple moving average of $84.68 and a 200-day simple moving average of $77.84. The company has a market capitalization of $19.84 billion, a P/E ratio of -17.58 and a beta of 0.90. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share. On average, analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. The Goldman Sachs Group boosted their target price on Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Royal Bank Of Canada boosted their target price on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Bank of America boosted their target price on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, Morgan Stanley boosted their target price on Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and a consensus target price of $108.07.

Insiders Place Their Bets

In related news, CFO Sara Bonstein sold 57,764 shares of the firm's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $95.86, for a total value of $5,537,257.04. Following the sale, the chief financial officer directly owned 84,017 shares of the company's stock, valued at $8,053,869.62. This trade represents a 40.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David W. J. Mcgirr sold 3,000 shares of the firm's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $73.27, for a total value of $219,810.00. Following the completion of the sale, the director directly owned 97,723 shares in the company, valued at $7,160,164.21. This trade represents a 2.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 548,197 shares of company stock valued at $49,124,834 over the last ninety days. 3.00% of the stock is owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.